Answers are grounded in this paper and cite their sources.
Myopia is now classified as a disease given that it may lead to significant complications such as retinal detachment, choroidal neovascularization, macular degeneration, posterior polar cataract, and glaucoma. Current interventions, which include pharmacological treatments and optical devices, are considered effective; however, they have limitations and unmet needs that require further research. This text presents the consensus reached by a group of international experts, including clinicians and researchers, to identify issues that remain to be resolved, as well as potential solutions that will help define myopia management 2.0. To be more precise, current interventions appear to reach a state of stabilization after the first year, demonstrating an incapacity to optimally manage the progression of myopia. In the absence of such optimized treatments, a multitude of issues need to be addressed, including the necessity for a better understanding of the drivers of eye growth; an improved way to educate parents and eye care professionals about myopia management options rather than merely correcting it; the enhancement of treatment algorithms to ensure greater personalisation; a broader promotion of life hygiene interventions; more research about the impact of treatment cessation; and the development of novel treatments that exhibit superior efficacy and are made readily available to the general population. Other suitable developments in the field include the creation of tools designed to accurately monitor the visual behavior of children with myopia. In addition, the potential of artificial intelligence to analyze large datasets, including identification of biomarkers are promising. Development of molecules to optimize the way they regulate retinal response to visual signals is also needed. The combination of these technologies with improved screening of patients at high risk and tailored interventions should result in improved outcomes for patients with myopia. Finally, following the example of authorities that have already adopted strict policies to control myopia—such as in China—other public agencies and governments should adopt regulations to help control this epidemic and ease access to eye care and efficient devices.
No takes yet. Share an insight, caveat, or question.
Michaud et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: